Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer - Top-Institutions - MDSpire

Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer

  • By

  • Wulphert Venderink

  • Marloes van der Leest

  • Annemarijke van Luijtelaar

  • Wendy J. M. van de Ven

  • Jurgen J. Fütterer

  • J. P. Michiel Sedelaar

  • Henkjan J. Huisman

  • September 4, 2017

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Urology
    • Radiology
    • Oncology

  • #2

    National Cancer Institute (NCI), NIH
    National Cancer Institute (NCI), NIH

    Bethesda, MD

    Key Differentiators

    • Urology
    • Radiology
    • Cancer Research

  • #3

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Urology
    • Radiology
    • Oncology

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Urology
    • Radiology
    • Oncology

  • #5

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Urology
    • Radiology
    • Oncology

Original Source(s)

Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer

  • by Wulphert Venderink, Marloes van der Leest, Annemarijke van Luijtelaar, Wendy J. M. van de Ven, Jurgen J. Fütterer, J. P. Michiel Sedelaar, Henkjan J. Huisman

  • September 4, 2017

Related Content

T2 mapping for the characterization of prostate lesions

Miniaturised ultrasound evaluation at the bedside

Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?